We are live on ! Find out more
ENTA icon

Enanta Pharmaceuticals
ENTA

124 hedge funds and large institutions have $549M invested in Enanta Pharmaceuticals in 2014 Q4 according to their latest regulatory filings, with 35 funds opening new positions, 36 increasing their positions, 42 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 21

35% more capital invested

Capital invested by funds: $408M → $549M (+$141M)

12% more funds holding

Funds holding: 111 → 124 (+13)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

14% less repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 42

62% less call options, than puts

Call options by funds: $1.13M | Put options by funds: $2.97M

Holders
124
Holders Change
+13
Holders Change %
+11.71%
% of All Funds
3.31%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.08%
New
35
Increased
36
Reduced
42
Closed
21
Calls
$1.13M
Puts
$2.97M
Net Calls
-$1.84M
Net Calls Change
-$857K

Top Buyers

1
ACM
Apex Capital Management
Ohio
+$24M
2
State Street
State Street
Massachusetts
+$17.8M
3
BFA
BlackRock Fund Advisors
California
+$11.5M
4
EAM
Eagle Asset Management
Florida
+$8.23M
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$5.67M

Top Sellers

1
SAM
Senzar Asset Management
New York
-$23.4M
2
RCM
RA Capital Management
Massachusetts
-$9.89M
3
GC
Guggenheim Capital
Illinois
-$7.39M
4
Marshall Wace
Marshall Wace
United Kingdom
-$5.45M
5
NI
Numeric Investors
Massachusetts
-$4.8M
Name Holding Trade Value Shares
Change 		Change in
Stake
Charles Schwab
26
Charles Schwab
California
$3.6M +$716K +15,988 +29%
BLM
27
Bennett Lawrence Management
New York
$3.35M -$2M -44,680 -40%
CCM
28
Cadence Capital Management
Massachusetts
$3.31M -$365K -8,162 -11%
Susquehanna International Group
29
Susquehanna International Group
Pennsylvania
$3.31M +$1.76M +39,346 +153%
AQR Capital Management
30
AQR Capital Management
Connecticut
$3M -$9.85K -220 -0.4%
TCIM
31
TIAA CREF Investment Management
New York
$2.99M -$45K -1,006 -2%
New York State Common Retirement Fund
32
New York State Common Retirement Fund
New York
$2.96M +$760K +16,976 +41%
BA
33
BlackRock Advisors
Delaware
$2.93M -$566K -12,644 -18%
RFC
34
Russell Frank Company
Washington
$2.61M +$253K +5,662 +12%
Wells Fargo
35
Wells Fargo
California
$2.58M +$1.11M +24,748 +95%
BJ
36
BlackRock Japan
Japan
$2.27M +$1.93M +43,018 +2,505%
ACP
37
Acuta Capital Partners
California
$2.26M +$1.99M +44,528 New
SAM
38
Senzar Asset Management
New York
$2.24M -$23.4M -522,786 -92%
GC
39
Guggenheim Capital
Illinois
$2.05M -$7.39M -165,062 -80%
SFM
40
Sphera Funds Management
Israel
$2.03M +$1.79M +40,000 New
CS
41
Candriam SCA
Luxembourg
$1.78M +$1.57M +35,000 New
DILH
42
Dai-ichi Life Holdings
Japan
$1.54M -$141K -3,150 -9%
BIM
43
BlackRock Investment Management
Delaware
$1.52M -$3.49K -78 -0.3%
Axa
44
Axa
France
$1.51M +$783K +17,500 +142%
NA
45
Navellier & Associates
Nevada
$1.46M +$1.29M +28,759 New
RFC
46
Regions Financial Corp
Alabama
$1.43M +$157K +3,506 +14%
Citadel Advisors
47
Citadel Advisors
Florida
$1.37M -$880K -19,658 -42%
TI
48
Turner Investments
Pennsylvania
$1.35M -$2.18M -48,610 -65%
PI
49
Putnam Investments
Massachusetts
$1.34M -$6.4K -143 -0.5%
PCM
50
Price Capital Management
Louisiana
$1.26M +$1.11M +24,807 New
1
2
3 4 5

ENTA Hedge Fund Activity: Q4 2014 in Review

124 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q4 2014, worth a combined $549M — up 35% from $408M a quarter earlier.

Buyers outnumbered sellers: 35 funds opened new ENTA positions and 21 closed out — a net gain of 14 holders — while 36 added to existing stakes and 42 trimmed.

The largest buyer was Apex Capital Management, adding an estimated $24M. The largest seller was Senzar Asset Management, cutting an estimated $23.4M.

  • 124 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q4 2014, up from 111 in Q3 2014.
  • Funds reported $549M of Enanta Pharmaceuticals stock for Q4 2014, up 35% quarter-over-quarter.
  • 35 funds opened new Enanta Pharmaceuticals positions in Q4 2014 and 21 closed out, a net change of +14 holders.
  • The largest Enanta Pharmaceuticals buyer in Q4 2014 was Apex Capital Management, an estimated $24M added.
  • The largest Enanta Pharmaceuticals seller in Q4 2014 was Senzar Asset Management, an estimated $23.4M sold.

Based on aggregated 13F filings for Q4 2014.